Key inclusion Criteria:

• Signed Informed Consent Document

• Documented active diagnosis of metastatic pancreatic ductal adenocarcinoma

• Cachexia defined by Fearon criteria of weight loss

• Completed 1 x 28-day cycle of first-line systemic nab-paclitaxel and gemcitabine chemotherapy or 2 x 14-day cycles of FOLFIRINOX chemotherapy and prior to receiving Cycle 2 chemotherapy

• ECOG PS ≤1 with life expectancy of at least 4 months

Key Exclusion Criteria:

• Current active reversible causes of decreased food intake

• Cachexia caused by other reasons

• History of heart failure

• Left ventricular ejection fraction <50%

• Receiving tube feedings or parenteral nutrition at the time of Screening or Randomization

• History of allergic or anaphylactic reaction to any therapeutic or diagnostic monoclonal antibody

• History of allergy or hypersensitivity to any of the chemotherapeutics or any of their excipients

• Neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma, symptomatic brain metastasis, leptomeningeal disease or other active CNS metastases

• Inadequate liver function

• Renal disease requiring dialysis or eGFR <30 mL/min/1.73m2

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 11/7/2025. Questions regarding updates should be directed to the study team contact.